You are using an outdated browser. Please upgrade your browser to improve your experience and security.

VYXEOS is a chemotherapy that provides a potent delivery of 2 drugs at a synergistic ratio1

VYXEOS has been shown to deliver daunorubicin and cytarabine at a synergistic molar ratio and persist in the bone marrow for a prolonged period of time1-4

  • The synergistic 1:5 molar ratio of daunorubicin and cytarabine has been shown to enhance the killing of leukemia cells in vitro and in murine models1
  • This ratio was shown to be maintained in the plasma for up to 24 hours in a Phase 1 clinical trial4
  • The longer half-life of VYXEOS results in greater drug exposure within the plasma and bone marrow than traditional chemotherapy1,4
    • Estimated median half-life of daunorubicin was 32 hours with VYXEOS vs 19 hours as free drug1,5
    • Estimated median half life of cytarabine was 40 hours with VYXEOS vs approximately 1-3 hours as free drug1,6

See the overall survival data for VYXEOS compared to 7+3a in adults with newly-diagnosed secondary AML subtypes, t-AML or AML-MRC1

Key highlights

Based on animal studies…

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

IMPORTANT SAFETY INFORMATION

INDICATION

VYXEOS (daunorubicin and cytarabine) liposome for injection 44 mg/100 mg is indicated for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Important Safety Information

WARNING: DO NOT INTERCHANGE WITH OTHER DAUNORUBICIN AND/OR CYTARABINE-CONTAINING PRODUCTS

VYXEOS has different dosage recommendations than daunorubicin hydrochloride injection, cytarabine injection, daunorubicin citrate liposome injection, and cytarabine liposome injection. Verify drug name and dose prior to preparation and administration to avoid dosing errors.